Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
VIPR1 encodes a receptor for vasoactive intestinal peptide, a small neuropeptide. Additionally we are shipping Vasoactive Intestinal Peptide Receptor 1 Kits (10) and Vasoactive Intestinal Peptide Receptor 1 Proteins (5) and many more products for this protein.
Showing 10 out of 104 products:
Human Monoclonal VIPR1 Primary Antibody for FACS, WB - ABIN264524
Goetzl, Patel, Kishiyama, Smoll, Turck, Law, Rosenzweig, Sreedharan: Specific recognition of the human neuroendocrine receptor for vasoactive intestinal peptide by anti-peptide antibodies. in Molecular and cellular neurosciences 1994
Show all 3 references for ABIN264524
Human Polyclonal VIPR1 Primary Antibody for WB - ABIN1881994
Mlakar, Strazisar, Sok, Glavac: Oligonucleotide DNA microarray profiling of lung adenocarcinoma revealed significant downregulation and deletions of vasoactive intestinal peptide receptor 1. in Cancer investigation 2010
Show all 2 references for ABIN1881994
Implanting vascular bundles into the tissue engineered bone can significantly improve the expression levels of NK1R (show TACR1 Antibodies) and VIPR1.
VPAC1 rs9677 CC genotype could be correlated with a reduced response to statin therapy and seems to be involved in diabetes cardiomyopathy in female patients with type 2 diabetes.
The results reveal that more severe inflammation, based on high levels of IL-6 (show IL6 Antibodies), is associated with lower expression of VPAC1 and, conversely, with increased expression of VPAC2 (show VIPR2 Antibodies).
variations at the 3'UTR (show UTS2R Antibodies) of the VPAC-1 gene act synergistically to affect the expression of the luciferase as well as of the GFP reporter genes expressed in HEK293T cells.
These data suggest that VPAC1 overexpression is associated with poorer differentiation of colon cancer, which is likely caused by subsequent EGFR (show EGFR Antibodies) activation in cancer cells.
VIP (show Vip Antibodies) regulates CFTR (show CFTR Antibodies) membrane expression and function in Calu (show CALU Antibodies)-3 cells by increasing its interaction with NHERF1 (show SLC9A3R1 Antibodies) and P-ERM (show ETV5 Antibodies) in a VPAC1- and PKCepsilon (show PRKCE Antibodies)-dependent manner.
VPAC1 receptor has a role in endotoxemia in peripheral blood mononuclear cells
The overexpression of VPAC1 and VPAC2 (show VIPR2 Antibodies) receptors and COX-2 (show COX2 Antibodies) in cancer tissue gives them a potential role as targets for diagnosis of prostate cancer.
hree residues play an important role in VPAC1 interaction with the first histidine residue of VIP (show Vip Antibodies). These data demonstrate that VIP (show Vip Antibodies) and PG97-269 bind to distinct domains of VPAC1
The genetic association reported here indicates that VIP (show Vip Antibodies)/VPAC1 signaling can be a relevant pathway in the pathogenesis of type 2 diabetes in females
silencing of VPAC1 receptor inhibits vasoactive intestinal peptide effects on both EGF receptor and HER2 transactivation and vascular endothelial growth factor secretion in human breast cancer cells
VPAC1R mRNA expression was significantly decreased 3 days after ischemia induced by bilateral common carotid artery occlusion
Cyclophosphamide-induced cystitis decreased VPAC1 receptor transcript expression in the urothelium of WT (4 h, 48 h, & chronic) & NGF-OE mice.
Data support the notion that both VPAC1 and VPAC2 (show VIPR2 Antibodies) receptors are dynamically regulated by Ikaros (show IKZF1 Antibodies), a master transcriptional regulator for thymocyte differentiation, during early thymic development.
results support that decline in VIP (show Vip Antibodies)/VPAC local levels may influence survival/apoptosis intracellular set point in NOD acinar cells and their clearance, contributing to gland homeostasis loss in a model of Sjogren's syndrome
Homozygous deletion of VPAC1 resulted in fetal, neonatal, and postweaning death owing to failure to thrive, intestinal obstruction, and hypoglycemia.
VIP (show Vip Antibodies) enhancement of the severity of dextran sodium sulfate-induced colitis is mediated solely by VPAC1 receptors in mice.
Data describe PACAP, vasoactive intestinal polypeptide, and PAC1, VPAC1, VPAC2 transcripts or protein expression in urothelium and detrusor smooth muscle and lumbosacral dorsal root ganglia in NGF-overexpressing and wildtype mice.
VPAC(1)-R activation aggravates atherosclerotic lesion formation in apolipoprotein E (show APOE Antibodies)-deficient mice through enhanced inflammatory activity in the vessel wall.
VIP (show Vip Antibodies) and its receptors (VPAC1, VPAC2 (show VIPR2 Antibodies)) were identified in type II taste cells of the taste bud, and VIP (show Vip Antibodies) knockout mice exhibit enhanced taste preference to sweet tastants.
In contrast, selective VPAC(1) receptor activation shifts NSPC fate toward granule cell neurogenesis without any trophism.
The study confirmed the presence of VPAC1 receptor in the tissues of the porcine female reproductive tract what clearly shows the possibility of influence of vasoactive intestinal polypeptide (show Vip Antibodies) on the porcine ovary, oviduct and uterus.
This gene encodes a receptor for vasoactive intestinal peptide, a small neuropeptide. Vasoactive intestinal peptide is involved in smooth muscle relaxation, exocrine and endocrine secretion, and water and ion flux in lung and intestinal epithelia. Its actions are effected through integral membrane receptors associated with a guanine nucleotide binding protein which activates adenylate cyclase. Several transcript variants encoding different isoforms have been found for this gene.
vasoactive intestinal polypeptide receptor 1
, vasoactive intestinal peptide receptor 1
, vasoactive intestinal polypeptide receptor 1-like
, vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide receptor 1
, vpac1 receptor
, vasoactive intestinal polypeptide receptor type 1
, PACAP type II receptor
, VIP and PACAP receptor 1
, VIP receptor, type I
, pituitary adenylate cyclase activating polypeptide receptor, type II
, VIP receptor subtype 1
, pituitary adenylate cyclase-activating polypeptide type II receptor
, Vasopressive intestinal peptide receptor